An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Atresia

Interventions

DRUG: Odevixibat

Sponsor

Albireo, an Ipsen Company